Cognition Therapeutics, Inc. (CGTX)
NASDAQ: CGTX · Real-Time Price · USD
0.3170
+0.0780 (32.64%)
At close: Jun 2, 2025, 4:00 PM
0.3096
-0.0074 (-2.33%)
After-hours: Jun 2, 2025, 7:00 PM EDT
Cognition Therapeutics Employees
As of December 31, 2024, Cognition Therapeutics had 28 total employees, including 25 full-time and 3 part-time employees. The number of employees did not change compared to the previous year.
Employees
28
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,189,286
Market Cap
19.65M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28 | 0 | - |
Dec 31, 2023 | 28 | 3 | 12.00% |
Dec 31, 2022 | 25 | 4 | 19.05% |
Dec 31, 2021 | 21 | 1 | 5.00% |
Dec 31, 2020 | 20 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
CGTX News
- 5 days ago - Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies - GlobeNewsWire
- 24 days ago - Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health - GlobeNewsWire
- 26 days ago - Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update - GlobeNewsWire
- 2 months ago - Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes - GlobeNewsWire
- 2 months ago - Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025 - GlobeNewsWire
- 2 months ago - Cognition Therapeutics, Inc (CGTX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results - GlobeNewsWire